A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

Abstract Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidylinositol 3-kinase inhibitor, used in combination...

Full description

Bibliographic Details
Main Authors: Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Cancer
Subjects:
Gastrointestinal stromal tumor
GIST
Alpelisib
Imatinib
Sunitinib
Regorafenib
Online Access:https://doi.org/10.1186/s12885-022-09610-4

Internet

https://doi.org/10.1186/s12885-022-09610-4

Similar Items